Home Current Archive Editorial Team
About us
Aims and scope About Author Guidelines
News Contact
×
Home Current Archive Editorial board

Aims and scope About Author Guidelines
News Contact
Review paper
Received: 27.04.2022. >> Accepted: 21.06.2022. >> Published: 02.07.2022. Biochemistry
<< Prev | Next >>
PDF
https://doi.org/10.17392/1499-22

Vascular comorbidities in patients with multiple sclerosis and their impact on physical disability

By
Daliborka Tadić Orcid logo ,
Daliborka Tadić
Contact Daliborka Tadić

Clinic of Neurology, University Clinical Centre of the Republic of Srpska, Banjaluka, Bosnia and Herzegovina

Department of Neurology, School of Medicine, University of Banja Luka, Banjaluka, Bosnia and Herzegovina

View authors publications

Search this author on:

PubMed | Google Scholar
Sanja Grgić ,
Sanja Grgić

Department of Neurology, School of Medicine, University of Banja Luka, Banjaluka, Bosnia and Herzegovina

Clinic of Neurology, University Clinical Centre of the Republic of Srpska, Banjaluka, Bosnia and Herzegovina

View authors publications

Search this author on:

PubMed | Google Scholar
Aleksandra Dominović-Kovačević ,
Aleksandra Dominović-Kovačević

Clinic of Neurology, University Clinical Centre of the Republic of Srpska, Banjaluka, Bosnia and Herzegovina

Department of Neurology, School of Medicine, University of Banja Luka, Banjaluka, Bosnia and Herzegovina

View authors publications

Search this author on:

PubMed | Google Scholar
Majda Nazalević-Bursać ,
Majda Nazalević-Bursać

Clinic of Neurology, University Clinical Centre of the Republic of Srpska, Banjaluka, Bosnia and Herzegovina

View authors publications

Search this author on:

PubMed | Google Scholar
Srđan Mavija ,
Srđan Mavija

Clinic of Neurology, University Clinical Centre of the Republic of Srpska, Banja Luka, Bosnia and Herzegovina

View authors publications

Search this author on:

PubMed | Google Scholar
Vlado Đajić
Vlado Đajić

Clinic of Neurology, University Clinical Centre of the Republic of Srpska, Banja Luka, Bosnia and Herzegovina

Department of Neurology, School of Medicine, University of Banja Luka, Banja Luka, Bosnia and Herzegovina

View authors publications

Search this author on:

PubMed | Google Scholar

Abstract

Aim
Given the impact of vascular comorbidities (VC) on the diagnosis, treatment, and outcome of multiple sclerosis (MS), we
examined the incidence and correlation of VC and risk factors for vascular disease in people with MS (PwMS) compared to the general population, and the impact on the physical disability of patients.
Methods
Cross-sectional study involved 100 patients with MS and 50 healthy people from the general population, matched by
sex and age. The values of demographic, biochemical, and anthropometric parameters, the presence of VC and risk factors for vascular diseases in both groups, and clinical parameters in PwMS were analysed. Statistical analysis included methods of descriptive statistics, χ2 test, Student's t-test, analysis of variance, correlation
and regression analysis.
Results
Groups differed by a higher frequency of transient ischemic attack in the control group (p=0.024), and the treatment of
hypertension (p=0.038) and smoking frequency (p=0.044) in the MS group. Normal triglycerides levels were statistically significantly more prevalent in the MS group (p=0.000). Total body weight and BMI were statistically significantly higher in the control group (p=0.000). The increase in Expanded Disability Status Scale (EDSS) score was associated with higher levels of total (p=0.001) and low-density lipoprotein (LDL) cholesterol (p=0.003), and activated partial thromboplastin time APTT (p=0.002).
Conclusion
In PwMS it is necessary to pay attention to the higher frequency of smoking than in general population, and the impact
of total cholesterol, LDL and APTT levels as significant parameters that affect physical disability.

Keywords:

cholesterol,
hypertension,
smoking,
vascular diseases

References

1.
Zhang T, Tremlett H, Zhu F, Kingwell E, Fisk J, Bhan V, et al. Effects of physical comorbidities on disability progression in multiple sclerosis. Neurology. 2018. p. 419–27.
2.
Gil-González I, Martín-Rodríguez A, Conrad R, Pérez-San-Gregorio M. Quality of life in adults with multiple sclerosis: a systematic review. BMJ Open. 2020. p. 41249.
3.
Magyari M, Sorensen P. Comorbidity in multiple sclerosis. Front Neurol. 2020. p. 851.
4.
Hauer L, Perneczky J, Sellner J. A global view of comorbidity in multiple sclerosis: a systematic review with a focus on regional differences, methodology, and clinical implications. J Neurol. 2021. p. 4066–77.
5.
Diržiuvienė B, Mickevičienė D. Comorbidity in multiple sclerosis: Emphasis on patient-reported outcomes. Mult Scler Relat Disord. 2022. p. 103558.
6.
Arnett D, Blumenthal R, Albert M, Buroker A, Goldberger Z, Hahn E, et al. ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019. p. 140-e596.
7.
Kurtzke J. Rating neurologic instrument in multiple sclerosis: An expanded disability status scale (EDSS). Neurology. 1983. p. 1444–52.
8.
Fellows M, Bhattacharya S, Bodziak M, Jakimovski D, Hagemeier J, Browne R, et al. Oxysterols and apolipoproteins in multiple sclerosis: a 5-year follow-up study. J Lipid Res. 2019. p. 1190–8.
9.
Isshiki M, Hirayama S, Ueno T, Ito M, Furuta A, Yano K, et al. Apolipoproteins C-II and C-III as nutritional markers unaffected by inflammation. Clin Chim Acta. 2018. p. 225–30.
10.
Pašić B, Tudor M, Mustač K, Rajič F, Pašić F, Vujević H, et al. Comorbidities in patients with multiple sclerosis in Croatia. Psychiatr Danub. 2021. p. 475–9.
11.
Ajdacic-Gross V, Steinemann N, Horváth G, Rodgers S, Kaufmann M, Xu Y, et al. Onset symptom clusters in multiple sclerosis: characteristics, comorbidities, and risk factors. Front Neurol. 2021. p. 693440.
12.
Piluti L, Molti R. Body composition and disability in people with multiple sclerosis. A dual energy x-ray absorptiometry study. Mult Scler Relat Disord. 2019. p. 41–7.
13.
Jakimovski D, Guan Y, Ramanathan M, Weinstock-Guttman B, Zivadinov R. Lifestyle-based modifiable risk factors in multiple sclerosis: review of experimental and clinical findings. Neurodegener Dis Manag. 2019. p. 149–72.
14.
Hedström A. Smoking and its interaction with genetics in MS etiology. Mult Scler. 2019. p. 180–6.
15.
Waubant E, Lucas R, Mowry E, Graves J, Olsson T, Alfredsson L, et al. Environmental and genetic risk factors for MS: an integrated review. Ann Clin Transl Neurol. 2019. p. 1905–22.
16.
Arneth B. Multiple Sclerosis and smoking. Am J Med. 2020. p. 783–8.
17.
Auer M, Bsteh G, Hegen H, Pauli D, Wurth F, Berger S, et al. Smoking is not associated with higher prevalence of JC virus in MS patients. Eur J Clin Microbiol Infect Dis. 2018. p. 907–10.
18.
Bang Oturai A, Sellebjerg F, Søndergaard H, Sørensen S, Olsson P, Laursen A, et al. Smoking is associated with increased disease activity during natalizumab treatment in multiple sclerosis. Mult Scler J. 2018. p. 1298–305.
19.
Passali M, Josefsen K, Frederiksen J, Antvorskov J. Current evidence on the efficacy of gluten-free diets in multiple sclerosis, psoriasis, type 1 diabetes and autoimmune thyroid diseases. Nutrients. 2020. p. 2316.
20.
Moss B, Rensel M, Hersh C. Wellness and the role of comorbidities in multiple sclerosis. Neurotherapeutics. 2017. p. 999–1017.
21.
Berrigan L, Fisk J, Patten S, Tremlett H, Wolfson C, Warren S, et al. CIHR Team in the Epidemiology and Impact of Comorbidity on Multiple Sclerosis (ECoMS). Healthrelated quality of life in multiple sclerosis: direct and indirect effects of comorbidity. Neurology. 2016. p. 1417–24.
22.
Palladino R, Marrie R, Majeed A, Chataway J. Evaluating the risk of macrovascular events and mortality among people with multiple sclerosis in England. JAMA Neurol. 2020. p. 820–8.
23.
Persson R, Lee S, Yood M, Wagner M, Minton N, Niemcryk S, et al. Multidatabase study of multiple sclerosis: identification, validation and description of MS patients in two countries. J Neurol. 2019. p. 1095–106.
24.
Jalkh G, Nahed A, Macaron R, Rensel G, M. Safety of newer disease modifying therapies in multiple sclerosis. Vaccines. 2020. p. 12.
25.
Stampanoni B, Iezzi E, Buttari F, Gilio L, Simonelli I, Carbone F, et al. Obesity worsens central inflammation and disability in multiple sclerosis. Mult Scler. 2020. p. 1237–46.
26.
Ziliotto N, Bernardi F, Jakimovski D, Zivadinov R. Coagulation pathways in neurological diseases: multiple sclerosis. Front Neurol. 2019. p. 409.
27.
Koudriavtseva T, Stefanile A, Fiorelli M, Lapucci C, Lorenzano S, Zannino S, et al. Coagulation/complement activation and cerebral hypoperfusion in relapsing-remitting multiple sclerosis. Front Immunol. 2020. p. 548604.

Citation

Copyright

Authors retain copyright. This work is licensed under a Creative Commons Attribution 4.0 International License. Creative Commons License

 

Article metrics

Google scholar: See link

{{ submission.title }}
Issue image
Vol 19, Issue 2, 2022
Obstetric shock and shock in obstetrics – steady obstetrical syndrome Pheochromocytoma in pregnancy – a rare but dangerous diagnosis A comparison of different doses of fentanyl for patients undergoing elective colonoscopy: a randomized double-blind clinical trial The effect of statin administration on IL-6 and IL-1b expression in peripheral blood mononuclear cells of a hypertensive patient with SARS-CoV-2 spike protein stimulation Association between donor’s age and expression of cardiomyocyte marker quantity on adipocyte-derived mesenchymal stem cell See full issue

The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.